News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates L.A. McKeown January 10, 2025
News Daily News Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis Todd Neale November 28, 2024
News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024